An ambitious feat? Yes.
But so were all of the great accomplished feats you see here.
We believe that a cancer patient should not have to look or feel like a cancer patient. No hair loss, no nausea and vomiting. We believe cancer patients like all of us should not just 'live' but be able to enjoy life.
AlloOnc offers a bold new approach to cancer therapy - one in which non-cancerous healthy cells are left to live on. Our "smart" therapeutic approach is based on the work that our founders began as graduate students in Northern California, and is poised to change the way the medical community and regulatory agents, like the FDA, around the world, look at cancer therapies.
We may not be able to prevent cancer from occurring, but we can prevent recurrence and metastasis (spread of cancer). With your support we can develop this therapeutic into a real cure.
At AlloOnc, the patients we serve are human. But we look forward to extending our therapies to also help companion animals, because our pet dogs, cats, and horses are part of the family too.
Looking where others have not
We have known for a long time that cancer spreads. This is called metastasis. But until recently, the precise mechanisms of metastases were not examined in depth.
This is analogous to the Moai statues of Easter Island. Although it was suspected for decades that that the great Moai head statues also have bodies, it was not until recently (2010, 2011) that controlled excavations were finally made. These excavations revealed that the bodies actually go much deeper than suspected AND that ancient petroglyphs are carved upon them. Only now, with these excavations are solid hypotheses being made as to how Moai were transported.
We too believe in looking below the surface, and taking a different approach in exploring greater solutions. Recent studies have revealed molecular markers and proteins directly involved in the metastatic process that allows cancers cells to spread to distant parts of the body. Similarly, the role and formation of pre-metastatic niches are being revealed. These are AlloOnc's targets and have thus far led to the invention of a novel cellular smart therapeutic which we are developing and hope to soon take to clinical trials.
Just about everywhere, medical experts report that early detection is key. We believe the same is true even after cancer has been detected. Our diagnostic will seek out metastatic cancer cells that have broken away from the primary tumor and are spreading, but it will do so even for a few cells, before a clinically relevant metastatic tumor has formed.